8. Huntington disease Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 242 / Drugs : 205 - (DrugBank : 62) / Drug target genes : 85 - Drug target pathways : 159
Drugs and their primary sponsors and trial info
(2)-epigallocatechin-3-gallate (EGCG)
Charite University, Berlin, Germany
2011 Phase 2 NCT01357681 Germany;
18F-FDG
Universitaire Ziekenhuizen Leuven
2020 - NCT04701580 Belgium;
5-Chloro-1,2-dihydro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-3-quinolinecarboxamide sodium
Teva Branded Pharmaceutical Products R&D, Inc.
2015 Phase 2 EUCTR2014-000418-75-NL Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
2015 Phase 2 EUCTR2014-000418-75-GB Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
2015 Phase 2 EUCTR2014-000418-75-DE Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
2015 Phase 2 EUCTR2014-000418-75-CZ Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
2014 Phase 2 EUCTR2014-000418-75-PT Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
2014 Phase 2 EUCTR2014-000418-75-IT Canada;Czech Republic;France;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2014 Phase 2 EUCTR2014-000418-75-ES Canada;Czech Republic;France;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
ACR16
A. Carlsson Research AB
2004 - EUCTR2004-000394-60-SE Denmark;Sweden;
2004 - EUCTR2004-000394-60-DK Denmark;Sweden;
NEUROSEARCH SWEDEN AB
2008 - EUCTR2007-004988-22-IT Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom;
NeuroSearch Sweden AB
2009 - EUCTR2007-004988-22-AT Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004988-22-PT Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004988-22-GB Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004988-22-FR Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004988-22-ES Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004988-22-DE Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004988-22-BE Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom;
Teva Pharmaceutical Industries
2008 Phase 3 NCT00665223 Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom;
2008 Phase 2/Phase 3 NCT00724048 Canada;United States;
ACR16 hydrochloride, ASP2314 hydrochloride, FR310826
TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC
2015 Phase 2 EUCTR2015-000904-24-IT Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
Teva Branded Pharmaceutical Products R&D, Inc
2016 Phase 2 EUCTR2015-000904-24-NL Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2015 Phase 2 EUCTR2015-000904-24-GB Australia;Austria;Canada;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2015 Phase 2 EUCTR2015-000904-24-DE Australia;Austria;Canada;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2015 Phase 2 EUCTR2015-000904-24-AT Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2015 Phase 2 EUCTR2013-001888-23-DK Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2014 Phase 2 EUCTR2013-001888-23-PL Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2014 Phase 2 EUCTR2013-001888-23-NL Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2014 Phase 2 EUCTR2013-001888-23-IT Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2014 Phase 2 EUCTR2013-001888-23-DE Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2014 Phase 2 EUCTR2013-001888-23-AT Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2014 - EUCTR2013-001888-23-GB Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
ADENO-ASSOCIATED VIRUS SEROTYPE 5 ENCODING A MICRORNA TARGETED TO HUMAN HUNTINGTIN GENE
uniQure biopharma B.V.
2021 Phase 1;Phase 2 EUCTR2020-001461-36-PL Poland;United Kingdom;
AFQ056
Novartis Pharma Services AG
2009 - EUCTR2009-011743-39-GB Germany;United Kingdom;
2009 - EUCTR2009-011743-39-DE Germany;United Kingdom;United States;
Novartis Pharmaceuticals
2009 Phase 2 NCT01019473 Germany;United Kingdom;
AMT-130
uniQure biopharma B.V.
2021 Phase 1;Phase 2 EUCTR2020-001461-36-PL Poland;United Kingdom;
2021 Phase 1;Phase 2 EUCTR2020-001461-36-DE Germany;Poland;
ANX005
Annexon, Inc.
2020 Phase 2 NCT04514367 United States;
Alprazolam
Pfizer
2009 Phase 1 NCT00975481 Canada;
Amantadine
National Institute of Neurological Disorders and Stroke (NINDS)
1999 Phase 2 NCT00001930 United States;
Anti-Parkinson medication
Beth Israel Deaconess Medical Center
2016 - NCT02994719 United States;
Atomoxetine
University of Iowa
2005 Phase 2 NCT00368849 United States;
Autologous Stem Cell
Chaitanya Hospital, Pune
2014 Phase 1/Phase 2 NCT01834053 India;
BEVANTOLOL HYDROCHLORIDE
SOM Biotech
2018 Phase 2 EUCTR2018-000203-16-ES Spain;
BID of PF-02545920
Pfizer
2015 Phase 2 NCT02342548 Canada;Germany;Poland;United Kingdom;United States;
BN82451B
Ipsen
2014 Phase 2 NCT02231580 Germany;
Ipsen Pharma
2014 Phase 2 EUCTR2013-002899-41-DE Germany;
BN8251B
Ipsen Pharma
2014 Phase 2 EUCTR2013-002899-41-DE Germany;
Benerva
Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (Ciberned)
2021 Phase 2 EUCTR2019-004360-22-ES Spain;
BioStamp nPoint device
University of Rochester
2020 Phase 2 NCT04201834 United States;
Biotina
Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (Ciberned)
2021 Phase 2 EUCTR2019-004360-22-ES Spain;
Blood sample
University Hospital, Angers
2017 - NCT03296176 France;
Branaplam
Novartis Pharmaceuticals
2021 Phase 2 NCT05111249 Canada;France;Germany;Hungary;Spain;
Bupropion
Charite University, Berlin, Germany
2012 Phase 2 NCT01914965 Germany;
CKD-504
Chong Kun Dang Pharmaceutical
2018 Phase 1 NCT03713892 Korea, Republic of;
Calvan®
SOM Biotech
2018 Phase 2 EUCTR2018-000203-16-ES Spain;
Cellavita HD Higher dose
Azidus Brasil
2017 Phase 1 NCT02728115 Brazil;
Cellavita HD Lower Dose
Azidus Brasil
2017 Phase 1 NCT02728115 Brazil;
Cellavita HD higher dose
Azidus Brasil
2018 Phase 2 NCT03252535 Brazil;
Cellavita HD lower dose
Azidus Brasil
2018 Phase 2 NCT03252535 Brazil;
Cellavita-HD
Azidus Brasil
2020 Phase 2/Phase 3 NCT04219241 Brazil;
CoQ10
Johns Hopkins University
2010 Phase 2 NCT00920699 United States;
Coenzyme Q10
Massachusetts General Hospital
2008 Phase 3 NCT00608881 Australia;Canada;United States;
Creatine
National Center for Complementary and Integrative Health (NCCIH)
2001 Phase 1/Phase 2 NCT00026988 United States;
Creatine Monohydrate
Massachusetts General Hospital
2009 Phase 3 NCT00712426 Australia;Canada;New Zealand;United States;
2009 Phase 2 NCT01411150 United States;
Creatine monohydrate
Massachusetts General Hospital
2010 Phase 2 NCT01411163 United States;
2007 Phase 2 NCT00592995 United States;
2005 Phase 2 NCT01412151 United States;
Cysteamine Bitartrate
Centre Hospitalier Universitaire d'Angers
2010 - EUCTR2010-019444-39-FR France;
Deep Brain Stimulation
Beth Israel Deaconess Medical Center
2016 - NCT02994719 United States;
Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
2011 Phase 2 NCT01502046 Spain;
Deutetrabenazine
Vanderbilt University Medical Center
2021 Phase 2/Phase 3 NCT04713982 United States;
Deutetrabenazine Oral Tablet [Austedo]
Fundacion Huntington Puerto Rico
2020 Phase 1 NCT04301726 -
Second Affiliated Hospital, School of Medicine, Zhejiang University
2020 Phase 1 NCT04071639 China;
Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg)
The University of Texas Health Science Center, Houston
2019 Phase 3 NCT03854019 United States;
Digoxin
Pfizer
2009 Phase 1 NCT00831506 United States;
Dimebon
Medivation, Inc.
2009 Phase 3 NCT00920946 Australia;Canada;Denmark;Germany;Sweden;United Kingdom;United States;
2007 Phase 2 NCT00497159 United States;
2006 Phase 1/Phase 2 NCT00387270 United States;
Pfizer
2009 Phase 1 NCT00975481 Canada;
2009 Phase 1 NCT00831506 United States;
2009 Phase 1 NCT00827034 United States;
2009 Phase 1 NCT00825084 United States;
2009 Phase 1 NCT00824590 United States;
Dimebon (latrepirdine)
Medivation, Inc.
2010 Phase 3 NCT01085266 -
Dimebon + Dextromethorphan
Pfizer
2008 Phase 1 NCT00788047 United States;
Dimebon + Ketoconazole
Pfizer
2009 Phase 1 NCT00931073 United States;
Dimebon + Omeprazole
Pfizer
2009 Phase 1 NCT00931073 United States;
Dimebon Dihydrochloride
Medivation, Inc.
2007 Phase 2 EUCTR2007-003293-25-GB United Kingdom;
Dimebon IR
Pfizer
2009 Phase 1 NCT00990613 United States;
Dimebon IR Tablet
Pfizer
2009 Phase 1 NCT00988624 United States;
Dimebon MR1
Pfizer
2009 Phase 1 NCT00988624 United States;
Dimebon MR2
Pfizer
2009 Phase 1 NCT00988624 United States;
Dimebon MR3
Pfizer
2009 Phase 1 NCT00988624 United States;
Dimebon MR4
Pfizer
2009 Phase 1 NCT00988624 United States;
Dimebon Transdermal
Pfizer
2009 Phase 1 NCT00990613 United States;
Dimebon alone
Pfizer
2009 Phase 1 NCT00931073 United States;
Dimebon dihydrochloride
MEDIVATION, INC.
2010 - EUCTR2009-018123-32-IT Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom;
2009 - EUCTR2009-011800-44-IT Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom;
Medivation, Inc
2010 - EUCTR2009-018123-32-SE Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2009-018123-32-NL Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2009-018123-32-GB Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2009-018123-32-DK Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2009-018123-32-DE Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2009-011800-44-NL Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom;
2009 - EUCTR2009-011800-44-SE Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom;
2009 - EUCTR2009-011800-44-GB Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom;
2009 - EUCTR2009-011800-44-DK Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom;
2009 - EUCTR2009-011800-44-DE Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom;
Divalproex
National Institute of Neurological Disorders and Stroke (NINDS)
2004 Phase 2 NCT00095355 United States;
Ethyl Icosapent
Amarin Neuroscience Ltd
2006 - EUCTR2005-002088-98-PT Germany;Italy;Portugal;Spain;United Kingdom;
Ethyl-EPA
Amarin Neuroscience Ltd
2006 - EUCTR2005-002088-98-PT Germany;Italy;Portugal;Spain;United Kingdom;
2005 - EUCTR2005-002088-98-GB Germany;Italy;Portugal;Spain;United Kingdom;
2005 - EUCTR2005-002088-98-ES Germany;Italy;Portugal;Spain;United Kingdom;
2005 - EUCTR2005-002088-98-AT Austria;Germany;Italy;Portugal;Spain;United Kingdom;
- - EUCTR2005-002088-98-DE Germany;Italy;Portugal;Spain;United Kingdom;
Ethyl-EPA (Miraxion™)
Amarin Neuroscience Ltd
2005 Phase 3 NCT00146211 Canada;United States;
Ethyl-Icosapent
Amarin Neuroscience Ltd
2005 - EUCTR2005-002088-98-AT Austria;Germany;Italy;Portugal;Spain;United Kingdom;
- - EUCTR2005-002088-98-DE Germany;Italy;Portugal;Spain;United Kingdom;
Fenofibrate
University of California, Irvine
2017 Phase 2 NCT03515213 United States;
GSK356278
GlaxoSmithKline
2011 Phase 1 NCT01602900 United Kingdom;
2011 Phase 1 NCT01573819 Netherlands;
Graft intracerebral of foetal neurons
Assistance Publique - Hôpitaux de Paris
2002 Phase 2 NCT00190450 France;
Haloperidol 2Mg Tab
Second Affiliated Hospital, School of Medicine, Zhejiang University
2020 Phase 1 NCT04071639 China;
High doses of Thiamine y Biotin
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
2022 Phase 2 NCT04478734 Spain;
ISIS 443139
Ionis Pharmaceuticals, Inc.
2015 Phase 1/Phase 2 NCT02519036 Canada;Germany;United Kingdom;
Idebenone
Second Affiliated Hospital, School of Medicine, Zhejiang University
2020 Phase 1 NCT04071639 China;
LAX-101
Amarin Neuroscience Ltd
2006 - EUCTR2005-002088-98-PT Germany;Italy;Portugal;Spain;United Kingdom;
2005 - EUCTR2005-002088-98-GB Germany;Italy;Portugal;Spain;United Kingdom;
2005 - EUCTR2005-002088-98-ES Germany;Italy;Portugal;Spain;United Kingdom;
2005 - EUCTR2005-002088-98-AT Austria;Germany;Italy;Portugal;Spain;United Kingdom;
- - EUCTR2005-002088-98-DE Germany;Italy;Portugal;Spain;United Kingdom;
LMI070
NOVARTIS PHARMA AG
2021 Phase 2 EUCTR2020-000105-92-IT Belgium;Canada;France;Germany;Hungary;Italy;Lithuania;Russian Federation;Spain;United Kingdom;United States;
Novartis Farmacéutica S.A.
2021 Phase 2 EUCTR2020-000105-92-ES Belgium;Canada;France;Germany;Hungary;Italy;Lithuania;Russian Federation;Spain;United Kingdom;United States;
Novartis Pharma AG
2022 Phase 2 EUCTR2020-000105-92-LT Belgium;Canada;France;Germany;Hungary;Italy;Lithuania;Russian Federation;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2020-000105-92-HU Belgium;Canada;France;Germany;Hungary;Italy;Lithuania;Russian Federation;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2020-000105-92-FR Belgium;Canada;France;Germany;Hungary;Italy;Lithuania;Russian Federation;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2020-000105-92-DE Belgium;Canada;France;Germany;Hungary;Italy;Lithuania;Russian Federation;Spain;United Kingdom;United States;
LPM3770164 sustained release tablet simulant
Luye Pharma Group Ltd.
2022 Phase 1 NCT05238701 China;
Laquinimod
Teva Branded Pharmaceutical Products R&D, Inc.
2014 Phase 2 NCT02215616 Canada;Czech Republic;Czechia;France;Germany;India;Israel;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
Laquinimod capsules
Teva Branded Pharmaceutical Products R&D, Inc.
2015 Phase 2 EUCTR2014-000418-75-NL Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
2015 Phase 2 EUCTR2014-000418-75-GB Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
2015 Phase 2 EUCTR2014-000418-75-DE Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
2015 Phase 2 EUCTR2014-000418-75-CZ Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
2014 Phase 2 EUCTR2014-000418-75-PT Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
2014 Phase 2 EUCTR2014-000418-75-IT Canada;Czech Republic;France;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2014 Phase 2 EUCTR2014-000418-75-ES Canada;Czech Republic;France;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
Lithium
National Institute of Neurological Disorders and Stroke (NINDS)
2004 Phase 2 NCT00095355 United States;
Melatonin
The University of Texas Health Science Center, Houston
2021 - NCT04421339 United States;
Memantine
Jody Corey-Bloom, MD, PhD
2004 Phase 4 NCT00652457 United States;
University of British Columbia
2011 Phase 2 NCT01458470 Canada;
Metformin
Instituto de Investigacion Sanitaria La Fe
2021 Phase 3 NCT04826692 -
Minocycline
FDA Office of Orphan Products Development
2001 Phase 1/Phase 2 NCT00029874 United States;
Merit Cudkowicz
2006 Phase 2/Phase 3 NCT00277355 Canada;United States;
Moderate doses of Thiamine y Biotin
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
2022 Phase 2 NCT04478734 Spain;
Neflamapimod
EIP Pharma Inc
2019 Phase 2 NCT03980938 United Kingdom;
EIP Pharma, Inc.
2019 Phase 2 EUCTR2018-004840-51-GB United Kingdom;
Nilotinib
Georgetown University
2018 Phase 1 NCT03764215 United States;
OMS643762
Omeros Corporation
2014 Phase 2 NCT02074410 United States;
OSU6162 similar to (-)-OSU 6162
A. Carlsson Research AB
2014 Phase 2 EUCTR2013-002545-10-SE Sweden;
Olanzapine
Assistance Publique - Hôpitaux de Paris
2009 Phase 3 NCT00632645 France;
PBF-999
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
2014 Phase 1 NCT02208934 Spain;
PBF-999 /
Palobiofarma SL
2016 Phase 1 NCT02907294 Spain;
PBT2
Prana Biotechnology Limited
2012 Phase 2 NCT01590888 Australia;United States;
PF-02545920
Pfizer
2014 Phase 2 NCT02197130 Canada;Germany;Poland;United Kingdom;United States;
2013 Phase 2 NCT01806896 France;
Pfizer Inc, 235 East 42nd Street, New York, NY 10017
2015 Phase 2 EUCTR2014-004900-31-DE Canada;Germany;Poland;United Kingdom;United States;
2014 Phase 2 EUCTR2014-001291-56-DE Canada;Germany;Poland;United Kingdom;United States;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017
2015 Phase 2 EUCTR2014-001291-56-GB Canada;Germany;Poland;United Kingdom;United States;
PL101
Prilenia Neurotherapeutics Ltd
2020 Phase 3 EUCTR2020-002822-10-IT Austria;Canada;Czech Republic;European Union;Germany;Italy;Netherlands;United Kingdom;United States;
Prilenia Neurotherapeutics Ltd.
2021 Phase 3 EUCTR2020-002822-10-NL Austria;Czech Republic;Germany;Netherlands;
2021 Phase 3 EUCTR2020-002822-10-CZ Austria;Canada;Czech Republic;European Union;Germany;Netherlands;United Kingdom;United States;
2021 Phase 3 EUCTR2020-002822-10-AT Austria;Canada;Czech Republic;European Union;Germany;Netherlands;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002822-10-DE Austria;Canada;Czech Republic;European Union;Germany;Netherlands;United Kingdom;United States;
PRIDOPIDINE HYDROCHLORIDE
Prilenia Neurotherapeutics Ltd
2020 Phase 3 EUCTR2020-002822-10-IT Austria;Canada;Czech Republic;European Union;Germany;Italy;Netherlands;United Kingdom;United States;
Prilenia Neurotherapeutics Ltd.
2021 Phase 3 EUCTR2020-002822-10-NL Austria;Czech Republic;Germany;Netherlands;
2021 Phase 3 EUCTR2020-002822-10-CZ Austria;Canada;Czech Republic;European Union;Germany;Netherlands;United Kingdom;United States;
2021 Phase 3 EUCTR2020-002822-10-AT Austria;Canada;Czech Republic;European Union;Germany;Netherlands;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002822-10-DE Austria;Canada;Czech Republic;European Union;Germany;Netherlands;United Kingdom;United States;
Phosphorus
Institut National de la Santé Et de la Recherche Médicale, France
2012 - NCT01696708 France;
Pridiopidine
Prilenia Neurotherapeutics Ltd.
2021 Phase 3 EUCTR2020-002822-10-NL Austria;Czech Republic;Germany;Netherlands;
2021 Phase 3 EUCTR2020-002822-10-CZ Austria;Canada;Czech Republic;European Union;Germany;Netherlands;United Kingdom;United States;
2021 Phase 3 EUCTR2020-002822-10-AT Austria;Canada;Czech Republic;European Union;Germany;Netherlands;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002822-10-DE Austria;Canada;Czech Republic;European Union;Germany;Netherlands;United Kingdom;United States;
Pridopidina
TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC
2015 Phase 2 EUCTR2015-000904-24-IT Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
Pridopidine
Prilenia
2020 Phase 3 NCT04556656 Austria;Canada;Czechia;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 2 NCT02494778 Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2014 Phase 2 NCT02006472 Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2011 Phase 2 NCT01306929 Canada;United States;
Teva Branded Pharmaceutical Products R&D, Inc
2016 Phase 2 EUCTR2015-000904-24-NL Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2015 Phase 2 EUCTR2015-000904-24-GB Australia;Austria;Canada;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2015 Phase 2 EUCTR2015-000904-24-DE Australia;Austria;Canada;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2015 Phase 2 EUCTR2015-000904-24-AT Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2015 Phase 2 EUCTR2013-001888-23-DK Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2014 Phase 2 EUCTR2013-001888-23-PL Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2014 Phase 2 EUCTR2013-001888-23-NL Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2014 Phase 2 EUCTR2013-001888-23-IT Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2014 Phase 2 EUCTR2013-001888-23-DE Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2014 Phase 2 EUCTR2013-001888-23-AT Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2014 - EUCTR2013-001888-23-GB Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
Pridopidine (90 mg)
Prilenia
2017 Phase 1 NCT03019289 Germany;
RAAV5-miHTT
uniQure biopharma B.V.
2021 Phase 1;Phase 2 EUCTR2020-001461-36-PL Poland;United Kingdom;
2021 Phase 1;Phase 2 EUCTR2020-001461-36-DE Germany;Poland;
RG6042, formerly ISIS 443139, IONIS-HTTRx
F. HOFFMANN - LA ROCHE LTD.
2019 Phase 3 EUCTR2018-002987-14-IT Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Japan;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
F.Hoffmann La-Roche Ltd
2020 Phase 3 EUCTR2018-003898-94-NL Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2020 Phase 3 EUCTR2018-003898-94-AT Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003898-94-GB Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002987-14-PL Argentina;Australia;Austria;Canada;China;Denmark;France;Germany;Italy;Japan;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002987-14-NL Argentina;Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002987-14-GB Argentina;Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002987-14-DK Argentina;Australia;Austria;Canada;Chile;China;Denmark;France;Germany;Italy;Japan;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002987-14-AT Argentina;Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002471-25-DE Canada;Germany;United Kingdom;
2018 Phase 1;Phase 2 EUCTR2017-002471-25-GB Canada;Germany;United Kingdom;
Roche Farma S.A(Soc. Unipersonal) que realiza el ensayo en España y actúa como representante de F. Hoffmann-La Roche LTD
2019 Phase 3 EUCTR2018-003898-94-ES Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
RO7234292
Hoffmann-La Roche
2019 Phase 3 NCT03761849 Argentina;Australia;Austria;Canada;Chile;China;Denmark;France;Germany;Italy;Japan;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
RO7234292 (RG6042)
Hoffmann-La Roche
2019 Phase 3 NCT03842969 Argentina;Australia;Austria;Canada;Chile;Germany;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States;
2019 Phase 1 NCT04000594 Netherlands;United Kingdom;
2018 Phase 2 NCT03342053 Canada;Germany;United Kingdom;
RP 103
Centre Hospitalier Universitaire d'Angers
2010 - EUCTR2010-019444-39-FR France;
RP103
University Hospital, Angers
2010 Phase 2/Phase 3 NCT02101957 France;
Ramelteon
Massachusetts General Hospital
2009 - NCT00907595 United States;
Resveratrol
Assistance Publique - Hôpitaux de Paris
2015 - NCT02336633 France;
Rilmenidine
Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
2010 Phase 2 EUCTR2009-018119-14-GB United Kingdom;
Riluzole
Sanofi
1999 Phase 3 NCT00277602 -
Risperidone
University of Rochester
2020 Phase 2 NCT04201834 United States;
Risperidone 1Mg Tab
Second Affiliated Hospital, School of Medicine, Zhejiang University
2020 Phase 1 NCT04071639 China;
Ro 723-4292/F02
F. HOFFMANN - LA ROCHE LTD.
2020 Phase 3 EUCTR2018-003898-94-IT Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002987-14-IT Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Japan;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
F.Hoffmann La-Roche Ltd
2020 Phase 3 EUCTR2018-003898-94-NL Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2020 Phase 3 EUCTR2018-003898-94-AT Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003898-94-GB Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002987-14-PL Argentina;Australia;Austria;Canada;China;Denmark;France;Germany;Italy;Japan;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002987-14-NL Argentina;Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002987-14-GB Argentina;Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002987-14-DK Argentina;Australia;Austria;Canada;Chile;China;Denmark;France;Germany;Italy;Japan;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002987-14-AT Argentina;Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002471-25-DE Canada;Germany;United Kingdom;
2018 Phase 1;Phase 2 EUCTR2017-002471-25-GB Canada;Germany;United Kingdom;
Roche Farma S.A(Soc. Unipersonal) que realiza el ensayo en España y actúa como representante de F. Hoffmann-La Roche LTD
2019 Phase 3 EUCTR2018-003898-94-ES Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
Rolipram
GlaxoSmithKline
2011 Phase 1 NCT01602900 United Kingdom;
SAGE-718
Sage Therapeutics
2021 Phase 2 NCT05107128 -
2019 Phase 1 NCT03787758 United States;
SBT-020
Stealth Bio Therapeutics Inc
2017 Phase 2 EUCTR2016-003730-25-NL Netherlands;
SD-809
Auspex Pharmaceuticals, Inc.
2013 Phase 3 NCT01897896 Australia;Canada;United States;
Teva Pharmaceutical Industries
2013 Phase 3 NCT01795859 Australia;Canada;United States;
SEN0014196
SIENA BIOTECH SPA
2011 - EUCTR2011-001131-23-IT Germany;Italy;United Kingdom;
Siena Biotech S.p.A.
2011 Phase 2 NCT01521585 Germany;
2011 Phase 1 NCT01485965 United States;
2009 Phase 1 NCT01521832 United Kingdom;
Siena Biotech SpA
2011 - EUCTR2011-001131-23-GB Germany;Italy;United Kingdom;
2011 - EUCTR2011-001131-23-DE Germany;Italy;United Kingdom;
SEN0014196 (High Dose)
Siena Biotech S.p.A.
2011 Phase 1 NCT01485952 Germany;
SEN0014196 (Low Dose)
Siena Biotech S.p.A.
2011 Phase 1 NCT01485952 Germany;
SOM3355 100mg BID
SOM Biotech SL
2018 Phase 2 NCT03575676 Spain;
SOM3355 200mg BID
SOM Biotech SL
2018 Phase 2 NCT03575676 Spain;
SRX246
Azevan Pharmaceuticals
2016 Phase 2 NCT02507284 United States;
SS-20
Stealth Bio Therapeutics Inc
2017 Phase 2 EUCTR2016-003730-25-NL Netherlands;
Selisistat
SIENA BIOTECH SPA
2011 - EUCTR2011-001131-23-IT Germany;Italy;United Kingdom;
Siena Biotech SpA
2011 - EUCTR2011-001131-23-GB Germany;Italy;United Kingdom;
2011 - EUCTR2011-001131-23-DE Germany;Italy;United Kingdom;
Sodium phenylbutyrate
University of Rochester
2005 Phase 2 NCT00212316 United States;
TV-5600
Teva Branded Pharmaceutical Products R&D, Inc.
2015 Phase 2 EUCTR2014-000418-75-NL Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
2015 Phase 2 EUCTR2014-000418-75-GB Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
2015 Phase 2 EUCTR2014-000418-75-DE Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
2015 Phase 2 EUCTR2014-000418-75-CZ Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
2014 Phase 2 EUCTR2014-000418-75-PT Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
2014 Phase 2 EUCTR2014-000418-75-IT Canada;Czech Republic;France;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2014 Phase 2 EUCTR2014-000418-75-ES Canada;Czech Republic;France;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
TV-7820
TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC
2015 Phase 2 EUCTR2015-000904-24-IT Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
Teva Branded Pharmaceutical Products R&D, Inc
2016 Phase 2 EUCTR2015-000904-24-NL Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2015 Phase 2 EUCTR2015-000904-24-GB Australia;Austria;Canada;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2015 Phase 2 EUCTR2015-000904-24-DE Australia;Austria;Canada;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2015 Phase 2 EUCTR2015-000904-24-AT Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2015 Phase 2 EUCTR2013-001888-23-DK Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2014 Phase 2 EUCTR2013-001888-23-PL Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2014 Phase 2 EUCTR2013-001888-23-NL Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2014 Phase 2 EUCTR2013-001888-23-IT Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2014 Phase 2 EUCTR2013-001888-23-DE Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2014 Phase 2 EUCTR2013-001888-23-AT Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2014 - EUCTR2013-001888-23-GB Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
Tetrabenazine
Prestwick Pharmaceuticals
2000 Phase 3 NCT00219804 -
William Ondo, MD
2018 Phase 4 NCT02509793 United States;
Tetrabenazine withdrawal
New York Medical College
2013 Phase 4 NCT01834911 United States;
Tiapridal
Assistance Publique - Hôpitaux de Paris
2009 Phase 3 NCT00632645 France;
Tominersen
F. HOFFMANN - LA ROCHE LTD.
2020 Phase 3 EUCTR2018-003898-94-IT Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
F.Hoffmann La-Roche Ltd
2020 Phase 3 EUCTR2018-003898-94-NL Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2020 Phase 3 EUCTR2018-003898-94-AT Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003898-94-GB Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
Triheptanoin
INSERM
2015 Phase 2 EUCTR2014-005112-42-NL France;Netherlands;
2015 Phase 2 EUCTR2014-005112-42-FR France;Netherlands;
Triheptanoin 1g/kg/day
Institut National de la Santé Et de la Recherche Médicale, France
2013 Phase 2 NCT01882062 France;
Triheptanoin oil
Institut National de la Santé Et de la Recherche Médicale, France
2015 Phase 2 NCT02453061 France;Netherlands;
UX007
INSERM
2015 Phase 2 EUCTR2014-005112-42-NL France;Netherlands;
2015 Phase 2 EUCTR2014-005112-42-FR France;Netherlands;
Ubiquinol
University of Rochester
2009 Phase 1 NCT00980694 United States;
Ursodiol
Oregon Health and Science University
2007 Phase 1 NCT00514774 United States;
VX-745
EIP Pharma, Inc.
2019 Phase 2 EUCTR2018-004840-51-GB United Kingdom;
VX15/2503
Vaccinex Inc.
2015 Phase 2 NCT02481674 Canada;United States;
Valbenazine
Neurocrine Biosciences
2020 Phase 3 NCT04400331 Canada;United States;
2019 Phase 3 NCT04102579 Canada;United States;
Vitamin B7
Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (Ciberned)
2021 Phase 2 EUCTR2019-004360-22-ES Spain;
WVE-003
Wave Life Sciences Ltd.
2021 Phase 1/Phase 2 NCT05032196 Australia;Canada;Denmark;France;Germany;Poland;Spain;United Kingdom;
Wave Life Sciences UK Limited
2022 Phase 1;Phase 2 EUCTR2020-004556-15-NL Australia;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Switzerland;United Kingdom;
2021 Phase 1;Phase 2 EUCTR2020-004556-15-PL Australia;Canada;Denmark;France;Germany;Italy;Poland;Spain;United Kingdom;
2021 Phase 1;Phase 2 EUCTR2020-004556-15-IT Australia;Canada;Denmark;France;Germany;Italy;Poland;Spain;United Kingdom;
2021 Phase 1;Phase 2 EUCTR2020-004556-15-FR Australia;Canada;Denmark;France;Germany;Poland;Spain;United Kingdom;
2021 Phase 1;Phase 2 EUCTR2020-004556-15-ES Australia;Canada;Denmark;France;Germany;Italy;Poland;Spain;United Kingdom;
2021 Phase 1;Phase 2 EUCTR2020-004556-15-DK Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
2021 Phase 1;Phase 2 EUCTR2020-004556-15-DE Australia;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Switzerland;United Kingdom;
WVE-120101
Wave Life Science Ltd.
2019 Phase 1;Phase 2 EUCTR2016-005095-10-FR Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;United States;
Wave Life Sciences Ltd.
2020 Phase 1/Phase 2 NCT04617847 Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
2017 Phase 1/Phase 2 NCT03225833 Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
Wave Life Sciences UK Limited
2020 Phase 2 EUCTR2019-003637-42-PL Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
2020 Phase 2 EUCTR2019-003637-42-FR Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
2020 Phase 2 EUCTR2019-003637-42-DK Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
2020 Phase 2 EUCTR2019-003637-42-DE Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
2019 Phase 1;Phase 2 EUCTR2016-005095-10-DK Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
2019 Phase 1;Phase 2 EUCTR2016-005095-10-DE Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
2018 Phase 1;Phase 2 EUCTR2016-005095-10-GB Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;United States;
WVE-120102
WAVE Life Sciences Ltd
2019 Phase 1;Phase 2 EUCTR2016-005142-39-FR Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;United States;
Wave Life Sciences Ltd.
2019 Phase 1/Phase 2 NCT04617860 Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
2017 Phase 1/Phase 2 NCT03225846 Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
Wave Life Sciences UK Limited
2020 Phase 2 EUCTR2019-002178-30-FR Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
2020 Phase 2 EUCTR2019-002178-30-DK Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
2020 Phase 2 EUCTR2019-002178-30-DE Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
2019 Phase 2 EUCTR2019-002178-30-PL Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
2019 Phase 1;Phase 2 EUCTR2016-005142-39-DK Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2016-005142-39-GB Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;United States;
- Phase 1;Phase 2 EUCTR2016-005142-39-DE Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;United States;
Warfarin
Pfizer
2009 Phase 1 NCT00827034 United States;
Xenazine
Assistance Publique - Hôpitaux de Paris
2009 Phase 3 NCT00632645 France;
Zoloft 50Mg Tablet
Second Affiliated Hospital, School of Medicine, Zhejiang University
2020 Phase 1 NCT04071639 China;
[123I]MNI-420
Institute for Neurodegenerative Disorders
2009 Phase 1 NCT00970229 United States;
[18F]FPEB
Institute for Neurodegenerative Disorders
2009 Phase 1 NCT00870974 United States;
daily citalopram
University of Iowa
2005 Phase 2 NCT00271596 United States;
Charite University, Berlin, Germany
2011 Phase 2 NCT01357681 Germany;
18F-FDG
Universitaire Ziekenhuizen Leuven
2020 - NCT04701580 Belgium;
5-Chloro-1,2-dihydro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-3-quinolinecarboxamide sodium
Teva Branded Pharmaceutical Products R&D, Inc.
2015 Phase 2 EUCTR2014-000418-75-NL Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
2015 Phase 2 EUCTR2014-000418-75-GB Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
2015 Phase 2 EUCTR2014-000418-75-DE Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
2015 Phase 2 EUCTR2014-000418-75-CZ Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
2014 Phase 2 EUCTR2014-000418-75-PT Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
2014 Phase 2 EUCTR2014-000418-75-IT Canada;Czech Republic;France;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2014 Phase 2 EUCTR2014-000418-75-ES Canada;Czech Republic;France;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
ACR16
A. Carlsson Research AB
2004 - EUCTR2004-000394-60-SE Denmark;Sweden;
2004 - EUCTR2004-000394-60-DK Denmark;Sweden;
NEUROSEARCH SWEDEN AB
2008 - EUCTR2007-004988-22-IT Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom;
NeuroSearch Sweden AB
2009 - EUCTR2007-004988-22-AT Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004988-22-PT Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004988-22-GB Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004988-22-FR Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004988-22-ES Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004988-22-DE Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom;
2008 - EUCTR2007-004988-22-BE Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom;
Teva Pharmaceutical Industries
2008 Phase 3 NCT00665223 Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom;
2008 Phase 2/Phase 3 NCT00724048 Canada;United States;
ACR16 hydrochloride, ASP2314 hydrochloride, FR310826
TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC
2015 Phase 2 EUCTR2015-000904-24-IT Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
Teva Branded Pharmaceutical Products R&D, Inc
2016 Phase 2 EUCTR2015-000904-24-NL Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2015 Phase 2 EUCTR2015-000904-24-GB Australia;Austria;Canada;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2015 Phase 2 EUCTR2015-000904-24-DE Australia;Austria;Canada;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2015 Phase 2 EUCTR2015-000904-24-AT Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2015 Phase 2 EUCTR2013-001888-23-DK Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2014 Phase 2 EUCTR2013-001888-23-PL Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2014 Phase 2 EUCTR2013-001888-23-NL Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2014 Phase 2 EUCTR2013-001888-23-IT Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2014 Phase 2 EUCTR2013-001888-23-DE Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2014 Phase 2 EUCTR2013-001888-23-AT Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2014 - EUCTR2013-001888-23-GB Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
ADENO-ASSOCIATED VIRUS SEROTYPE 5 ENCODING A MICRORNA TARGETED TO HUMAN HUNTINGTIN GENE
uniQure biopharma B.V.
2021 Phase 1;Phase 2 EUCTR2020-001461-36-PL Poland;United Kingdom;
AFQ056
Novartis Pharma Services AG
2009 - EUCTR2009-011743-39-GB Germany;United Kingdom;
2009 - EUCTR2009-011743-39-DE Germany;United Kingdom;United States;
Novartis Pharmaceuticals
2009 Phase 2 NCT01019473 Germany;United Kingdom;
AMT-130
uniQure biopharma B.V.
2021 Phase 1;Phase 2 EUCTR2020-001461-36-PL Poland;United Kingdom;
2021 Phase 1;Phase 2 EUCTR2020-001461-36-DE Germany;Poland;
ANX005
Annexon, Inc.
2020 Phase 2 NCT04514367 United States;
Alprazolam
Pfizer
2009 Phase 1 NCT00975481 Canada;
Amantadine
National Institute of Neurological Disorders and Stroke (NINDS)
1999 Phase 2 NCT00001930 United States;
Anti-Parkinson medication
Beth Israel Deaconess Medical Center
2016 - NCT02994719 United States;
Atomoxetine
University of Iowa
2005 Phase 2 NCT00368849 United States;
Autologous Stem Cell
Chaitanya Hospital, Pune
2014 Phase 1/Phase 2 NCT01834053 India;
BEVANTOLOL HYDROCHLORIDE
SOM Biotech
2018 Phase 2 EUCTR2018-000203-16-ES Spain;
BID of PF-02545920
Pfizer
2015 Phase 2 NCT02342548 Canada;Germany;Poland;United Kingdom;United States;
BN82451B
Ipsen
2014 Phase 2 NCT02231580 Germany;
Ipsen Pharma
2014 Phase 2 EUCTR2013-002899-41-DE Germany;
BN8251B
Ipsen Pharma
2014 Phase 2 EUCTR2013-002899-41-DE Germany;
Benerva
Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (Ciberned)
2021 Phase 2 EUCTR2019-004360-22-ES Spain;
BioStamp nPoint device
University of Rochester
2020 Phase 2 NCT04201834 United States;
Biotina
Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (Ciberned)
2021 Phase 2 EUCTR2019-004360-22-ES Spain;
Blood sample
University Hospital, Angers
2017 - NCT03296176 France;
Branaplam
Novartis Pharmaceuticals
2021 Phase 2 NCT05111249 Canada;France;Germany;Hungary;Spain;
Bupropion
Charite University, Berlin, Germany
2012 Phase 2 NCT01914965 Germany;
CKD-504
Chong Kun Dang Pharmaceutical
2018 Phase 1 NCT03713892 Korea, Republic of;
Calvan®
SOM Biotech
2018 Phase 2 EUCTR2018-000203-16-ES Spain;
Cellavita HD Higher dose
Azidus Brasil
2017 Phase 1 NCT02728115 Brazil;
Cellavita HD Lower Dose
Azidus Brasil
2017 Phase 1 NCT02728115 Brazil;
Cellavita HD higher dose
Azidus Brasil
2018 Phase 2 NCT03252535 Brazil;
Cellavita HD lower dose
Azidus Brasil
2018 Phase 2 NCT03252535 Brazil;
Cellavita-HD
Azidus Brasil
2020 Phase 2/Phase 3 NCT04219241 Brazil;
CoQ10
Johns Hopkins University
2010 Phase 2 NCT00920699 United States;
Coenzyme Q10
Massachusetts General Hospital
2008 Phase 3 NCT00608881 Australia;Canada;United States;
Creatine
National Center for Complementary and Integrative Health (NCCIH)
2001 Phase 1/Phase 2 NCT00026988 United States;
Creatine Monohydrate
Massachusetts General Hospital
2009 Phase 3 NCT00712426 Australia;Canada;New Zealand;United States;
2009 Phase 2 NCT01411150 United States;
Creatine monohydrate
Massachusetts General Hospital
2010 Phase 2 NCT01411163 United States;
2007 Phase 2 NCT00592995 United States;
2005 Phase 2 NCT01412151 United States;
Cysteamine Bitartrate
Centre Hospitalier Universitaire d'Angers
2010 - EUCTR2010-019444-39-FR France;
Deep Brain Stimulation
Beth Israel Deaconess Medical Center
2016 - NCT02994719 United States;
Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
2011 Phase 2 NCT01502046 Spain;
Deutetrabenazine
Vanderbilt University Medical Center
2021 Phase 2/Phase 3 NCT04713982 United States;
Deutetrabenazine Oral Tablet [Austedo]
Fundacion Huntington Puerto Rico
2020 Phase 1 NCT04301726 -
Second Affiliated Hospital, School of Medicine, Zhejiang University
2020 Phase 1 NCT04071639 China;
Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg)
The University of Texas Health Science Center, Houston
2019 Phase 3 NCT03854019 United States;
Digoxin
Pfizer
2009 Phase 1 NCT00831506 United States;
Dimebon
Medivation, Inc.
2009 Phase 3 NCT00920946 Australia;Canada;Denmark;Germany;Sweden;United Kingdom;United States;
2007 Phase 2 NCT00497159 United States;
2006 Phase 1/Phase 2 NCT00387270 United States;
Pfizer
2009 Phase 1 NCT00975481 Canada;
2009 Phase 1 NCT00831506 United States;
2009 Phase 1 NCT00827034 United States;
2009 Phase 1 NCT00825084 United States;
2009 Phase 1 NCT00824590 United States;
Dimebon (latrepirdine)
Medivation, Inc.
2010 Phase 3 NCT01085266 -
Dimebon + Dextromethorphan
Pfizer
2008 Phase 1 NCT00788047 United States;
Dimebon + Ketoconazole
Pfizer
2009 Phase 1 NCT00931073 United States;
Dimebon + Omeprazole
Pfizer
2009 Phase 1 NCT00931073 United States;
Dimebon Dihydrochloride
Medivation, Inc.
2007 Phase 2 EUCTR2007-003293-25-GB United Kingdom;
Dimebon IR
Pfizer
2009 Phase 1 NCT00990613 United States;
Dimebon IR Tablet
Pfizer
2009 Phase 1 NCT00988624 United States;
Dimebon MR1
Pfizer
2009 Phase 1 NCT00988624 United States;
Dimebon MR2
Pfizer
2009 Phase 1 NCT00988624 United States;
Dimebon MR3
Pfizer
2009 Phase 1 NCT00988624 United States;
Dimebon MR4
Pfizer
2009 Phase 1 NCT00988624 United States;
Dimebon Transdermal
Pfizer
2009 Phase 1 NCT00990613 United States;
Dimebon alone
Pfizer
2009 Phase 1 NCT00931073 United States;
Dimebon dihydrochloride
MEDIVATION, INC.
2010 - EUCTR2009-018123-32-IT Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom;
2009 - EUCTR2009-011800-44-IT Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom;
Medivation, Inc
2010 - EUCTR2009-018123-32-SE Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2009-018123-32-NL Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2009-018123-32-GB Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2009-018123-32-DK Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2009-018123-32-DE Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom;
2010 - EUCTR2009-011800-44-NL Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom;
2009 - EUCTR2009-011800-44-SE Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom;
2009 - EUCTR2009-011800-44-GB Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom;
2009 - EUCTR2009-011800-44-DK Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom;
2009 - EUCTR2009-011800-44-DE Denmark;Germany;Italy;Netherlands;Sweden;United Kingdom;
Divalproex
National Institute of Neurological Disorders and Stroke (NINDS)
2004 Phase 2 NCT00095355 United States;
Ethyl Icosapent
Amarin Neuroscience Ltd
2006 - EUCTR2005-002088-98-PT Germany;Italy;Portugal;Spain;United Kingdom;
Ethyl-EPA
Amarin Neuroscience Ltd
2006 - EUCTR2005-002088-98-PT Germany;Italy;Portugal;Spain;United Kingdom;
2005 - EUCTR2005-002088-98-GB Germany;Italy;Portugal;Spain;United Kingdom;
2005 - EUCTR2005-002088-98-ES Germany;Italy;Portugal;Spain;United Kingdom;
2005 - EUCTR2005-002088-98-AT Austria;Germany;Italy;Portugal;Spain;United Kingdom;
- - EUCTR2005-002088-98-DE Germany;Italy;Portugal;Spain;United Kingdom;
Ethyl-EPA (Miraxion™)
Amarin Neuroscience Ltd
2005 Phase 3 NCT00146211 Canada;United States;
Ethyl-Icosapent
Amarin Neuroscience Ltd
2005 - EUCTR2005-002088-98-AT Austria;Germany;Italy;Portugal;Spain;United Kingdom;
- - EUCTR2005-002088-98-DE Germany;Italy;Portugal;Spain;United Kingdom;
Fenofibrate
University of California, Irvine
2017 Phase 2 NCT03515213 United States;
GSK356278
GlaxoSmithKline
2011 Phase 1 NCT01602900 United Kingdom;
2011 Phase 1 NCT01573819 Netherlands;
Graft intracerebral of foetal neurons
Assistance Publique - Hôpitaux de Paris
2002 Phase 2 NCT00190450 France;
Haloperidol 2Mg Tab
Second Affiliated Hospital, School of Medicine, Zhejiang University
2020 Phase 1 NCT04071639 China;
High doses of Thiamine y Biotin
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
2022 Phase 2 NCT04478734 Spain;
ISIS 443139
Ionis Pharmaceuticals, Inc.
2015 Phase 1/Phase 2 NCT02519036 Canada;Germany;United Kingdom;
Idebenone
Second Affiliated Hospital, School of Medicine, Zhejiang University
2020 Phase 1 NCT04071639 China;
LAX-101
Amarin Neuroscience Ltd
2006 - EUCTR2005-002088-98-PT Germany;Italy;Portugal;Spain;United Kingdom;
2005 - EUCTR2005-002088-98-GB Germany;Italy;Portugal;Spain;United Kingdom;
2005 - EUCTR2005-002088-98-ES Germany;Italy;Portugal;Spain;United Kingdom;
2005 - EUCTR2005-002088-98-AT Austria;Germany;Italy;Portugal;Spain;United Kingdom;
- - EUCTR2005-002088-98-DE Germany;Italy;Portugal;Spain;United Kingdom;
LMI070
NOVARTIS PHARMA AG
2021 Phase 2 EUCTR2020-000105-92-IT Belgium;Canada;France;Germany;Hungary;Italy;Lithuania;Russian Federation;Spain;United Kingdom;United States;
Novartis Farmacéutica S.A.
2021 Phase 2 EUCTR2020-000105-92-ES Belgium;Canada;France;Germany;Hungary;Italy;Lithuania;Russian Federation;Spain;United Kingdom;United States;
Novartis Pharma AG
2022 Phase 2 EUCTR2020-000105-92-LT Belgium;Canada;France;Germany;Hungary;Italy;Lithuania;Russian Federation;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2020-000105-92-HU Belgium;Canada;France;Germany;Hungary;Italy;Lithuania;Russian Federation;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2020-000105-92-FR Belgium;Canada;France;Germany;Hungary;Italy;Lithuania;Russian Federation;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2020-000105-92-DE Belgium;Canada;France;Germany;Hungary;Italy;Lithuania;Russian Federation;Spain;United Kingdom;United States;
LPM3770164 sustained release tablet simulant
Luye Pharma Group Ltd.
2022 Phase 1 NCT05238701 China;
Laquinimod
Teva Branded Pharmaceutical Products R&D, Inc.
2014 Phase 2 NCT02215616 Canada;Czech Republic;Czechia;France;Germany;India;Israel;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
Laquinimod capsules
Teva Branded Pharmaceutical Products R&D, Inc.
2015 Phase 2 EUCTR2014-000418-75-NL Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
2015 Phase 2 EUCTR2014-000418-75-GB Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
2015 Phase 2 EUCTR2014-000418-75-DE Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
2015 Phase 2 EUCTR2014-000418-75-CZ Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
2014 Phase 2 EUCTR2014-000418-75-PT Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
2014 Phase 2 EUCTR2014-000418-75-IT Canada;Czech Republic;France;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2014 Phase 2 EUCTR2014-000418-75-ES Canada;Czech Republic;France;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
Lithium
National Institute of Neurological Disorders and Stroke (NINDS)
2004 Phase 2 NCT00095355 United States;
Melatonin
The University of Texas Health Science Center, Houston
2021 - NCT04421339 United States;
Memantine
Jody Corey-Bloom, MD, PhD
2004 Phase 4 NCT00652457 United States;
University of British Columbia
2011 Phase 2 NCT01458470 Canada;
Metformin
Instituto de Investigacion Sanitaria La Fe
2021 Phase 3 NCT04826692 -
Minocycline
FDA Office of Orphan Products Development
2001 Phase 1/Phase 2 NCT00029874 United States;
Merit Cudkowicz
2006 Phase 2/Phase 3 NCT00277355 Canada;United States;
Moderate doses of Thiamine y Biotin
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
2022 Phase 2 NCT04478734 Spain;
Neflamapimod
EIP Pharma Inc
2019 Phase 2 NCT03980938 United Kingdom;
EIP Pharma, Inc.
2019 Phase 2 EUCTR2018-004840-51-GB United Kingdom;
Nilotinib
Georgetown University
2018 Phase 1 NCT03764215 United States;
OMS643762
Omeros Corporation
2014 Phase 2 NCT02074410 United States;
OSU6162 similar to (-)-OSU 6162
A. Carlsson Research AB
2014 Phase 2 EUCTR2013-002545-10-SE Sweden;
Olanzapine
Assistance Publique - Hôpitaux de Paris
2009 Phase 3 NCT00632645 France;
PBF-999
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
2014 Phase 1 NCT02208934 Spain;
PBF-999 /
Palobiofarma SL
2016 Phase 1 NCT02907294 Spain;
PBT2
Prana Biotechnology Limited
2012 Phase 2 NCT01590888 Australia;United States;
PF-02545920
Pfizer
2014 Phase 2 NCT02197130 Canada;Germany;Poland;United Kingdom;United States;
2013 Phase 2 NCT01806896 France;
Pfizer Inc, 235 East 42nd Street, New York, NY 10017
2015 Phase 2 EUCTR2014-004900-31-DE Canada;Germany;Poland;United Kingdom;United States;
2014 Phase 2 EUCTR2014-001291-56-DE Canada;Germany;Poland;United Kingdom;United States;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017
2015 Phase 2 EUCTR2014-001291-56-GB Canada;Germany;Poland;United Kingdom;United States;
PL101
Prilenia Neurotherapeutics Ltd
2020 Phase 3 EUCTR2020-002822-10-IT Austria;Canada;Czech Republic;European Union;Germany;Italy;Netherlands;United Kingdom;United States;
Prilenia Neurotherapeutics Ltd.
2021 Phase 3 EUCTR2020-002822-10-NL Austria;Czech Republic;Germany;Netherlands;
2021 Phase 3 EUCTR2020-002822-10-CZ Austria;Canada;Czech Republic;European Union;Germany;Netherlands;United Kingdom;United States;
2021 Phase 3 EUCTR2020-002822-10-AT Austria;Canada;Czech Republic;European Union;Germany;Netherlands;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002822-10-DE Austria;Canada;Czech Republic;European Union;Germany;Netherlands;United Kingdom;United States;
PRIDOPIDINE HYDROCHLORIDE
Prilenia Neurotherapeutics Ltd
2020 Phase 3 EUCTR2020-002822-10-IT Austria;Canada;Czech Republic;European Union;Germany;Italy;Netherlands;United Kingdom;United States;
Prilenia Neurotherapeutics Ltd.
2021 Phase 3 EUCTR2020-002822-10-NL Austria;Czech Republic;Germany;Netherlands;
2021 Phase 3 EUCTR2020-002822-10-CZ Austria;Canada;Czech Republic;European Union;Germany;Netherlands;United Kingdom;United States;
2021 Phase 3 EUCTR2020-002822-10-AT Austria;Canada;Czech Republic;European Union;Germany;Netherlands;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002822-10-DE Austria;Canada;Czech Republic;European Union;Germany;Netherlands;United Kingdom;United States;
Phosphorus
Institut National de la Santé Et de la Recherche Médicale, France
2012 - NCT01696708 France;
Pridiopidine
Prilenia Neurotherapeutics Ltd.
2021 Phase 3 EUCTR2020-002822-10-NL Austria;Czech Republic;Germany;Netherlands;
2021 Phase 3 EUCTR2020-002822-10-CZ Austria;Canada;Czech Republic;European Union;Germany;Netherlands;United Kingdom;United States;
2021 Phase 3 EUCTR2020-002822-10-AT Austria;Canada;Czech Republic;European Union;Germany;Netherlands;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002822-10-DE Austria;Canada;Czech Republic;European Union;Germany;Netherlands;United Kingdom;United States;
Pridopidina
TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC
2015 Phase 2 EUCTR2015-000904-24-IT Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
Pridopidine
Prilenia
2020 Phase 3 NCT04556656 Austria;Canada;Czechia;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 2 NCT02494778 Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2014 Phase 2 NCT02006472 Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2011 Phase 2 NCT01306929 Canada;United States;
Teva Branded Pharmaceutical Products R&D, Inc
2016 Phase 2 EUCTR2015-000904-24-NL Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2015 Phase 2 EUCTR2015-000904-24-GB Australia;Austria;Canada;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2015 Phase 2 EUCTR2015-000904-24-DE Australia;Austria;Canada;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2015 Phase 2 EUCTR2015-000904-24-AT Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2015 Phase 2 EUCTR2013-001888-23-DK Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2014 Phase 2 EUCTR2013-001888-23-PL Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2014 Phase 2 EUCTR2013-001888-23-NL Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2014 Phase 2 EUCTR2013-001888-23-IT Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2014 Phase 2 EUCTR2013-001888-23-DE Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2014 Phase 2 EUCTR2013-001888-23-AT Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2014 - EUCTR2013-001888-23-GB Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
Pridopidine (90 mg)
Prilenia
2017 Phase 1 NCT03019289 Germany;
RAAV5-miHTT
uniQure biopharma B.V.
2021 Phase 1;Phase 2 EUCTR2020-001461-36-PL Poland;United Kingdom;
2021 Phase 1;Phase 2 EUCTR2020-001461-36-DE Germany;Poland;
RG6042, formerly ISIS 443139, IONIS-HTTRx
F. HOFFMANN - LA ROCHE LTD.
2019 Phase 3 EUCTR2018-002987-14-IT Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Japan;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
F.Hoffmann La-Roche Ltd
2020 Phase 3 EUCTR2018-003898-94-NL Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2020 Phase 3 EUCTR2018-003898-94-AT Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003898-94-GB Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002987-14-PL Argentina;Australia;Austria;Canada;China;Denmark;France;Germany;Italy;Japan;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002987-14-NL Argentina;Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002987-14-GB Argentina;Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002987-14-DK Argentina;Australia;Austria;Canada;Chile;China;Denmark;France;Germany;Italy;Japan;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002987-14-AT Argentina;Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002471-25-DE Canada;Germany;United Kingdom;
2018 Phase 1;Phase 2 EUCTR2017-002471-25-GB Canada;Germany;United Kingdom;
Roche Farma S.A(Soc. Unipersonal) que realiza el ensayo en España y actúa como representante de F. Hoffmann-La Roche LTD
2019 Phase 3 EUCTR2018-003898-94-ES Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
RO7234292
Hoffmann-La Roche
2019 Phase 3 NCT03761849 Argentina;Australia;Austria;Canada;Chile;China;Denmark;France;Germany;Italy;Japan;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
RO7234292 (RG6042)
Hoffmann-La Roche
2019 Phase 3 NCT03842969 Argentina;Australia;Austria;Canada;Chile;Germany;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States;
2019 Phase 1 NCT04000594 Netherlands;United Kingdom;
2018 Phase 2 NCT03342053 Canada;Germany;United Kingdom;
RP 103
Centre Hospitalier Universitaire d'Angers
2010 - EUCTR2010-019444-39-FR France;
RP103
University Hospital, Angers
2010 Phase 2/Phase 3 NCT02101957 France;
Ramelteon
Massachusetts General Hospital
2009 - NCT00907595 United States;
Resveratrol
Assistance Publique - Hôpitaux de Paris
2015 - NCT02336633 France;
Rilmenidine
Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
2010 Phase 2 EUCTR2009-018119-14-GB United Kingdom;
Riluzole
Sanofi
1999 Phase 3 NCT00277602 -
Risperidone
University of Rochester
2020 Phase 2 NCT04201834 United States;
Risperidone 1Mg Tab
Second Affiliated Hospital, School of Medicine, Zhejiang University
2020 Phase 1 NCT04071639 China;
Ro 723-4292/F02
F. HOFFMANN - LA ROCHE LTD.
2020 Phase 3 EUCTR2018-003898-94-IT Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002987-14-IT Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Japan;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
F.Hoffmann La-Roche Ltd
2020 Phase 3 EUCTR2018-003898-94-NL Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2020 Phase 3 EUCTR2018-003898-94-AT Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003898-94-GB Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002987-14-PL Argentina;Australia;Austria;Canada;China;Denmark;France;Germany;Italy;Japan;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002987-14-NL Argentina;Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002987-14-GB Argentina;Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002987-14-DK Argentina;Australia;Austria;Canada;Chile;China;Denmark;France;Germany;Italy;Japan;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002987-14-AT Argentina;Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002471-25-DE Canada;Germany;United Kingdom;
2018 Phase 1;Phase 2 EUCTR2017-002471-25-GB Canada;Germany;United Kingdom;
Roche Farma S.A(Soc. Unipersonal) que realiza el ensayo en España y actúa como representante de F. Hoffmann-La Roche LTD
2019 Phase 3 EUCTR2018-003898-94-ES Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
Rolipram
GlaxoSmithKline
2011 Phase 1 NCT01602900 United Kingdom;
SAGE-718
Sage Therapeutics
2021 Phase 2 NCT05107128 -
2019 Phase 1 NCT03787758 United States;
SBT-020
Stealth Bio Therapeutics Inc
2017 Phase 2 EUCTR2016-003730-25-NL Netherlands;
SD-809
Auspex Pharmaceuticals, Inc.
2013 Phase 3 NCT01897896 Australia;Canada;United States;
Teva Pharmaceutical Industries
2013 Phase 3 NCT01795859 Australia;Canada;United States;
SEN0014196
SIENA BIOTECH SPA
2011 - EUCTR2011-001131-23-IT Germany;Italy;United Kingdom;
Siena Biotech S.p.A.
2011 Phase 2 NCT01521585 Germany;
2011 Phase 1 NCT01485965 United States;
2009 Phase 1 NCT01521832 United Kingdom;
Siena Biotech SpA
2011 - EUCTR2011-001131-23-GB Germany;Italy;United Kingdom;
2011 - EUCTR2011-001131-23-DE Germany;Italy;United Kingdom;
SEN0014196 (High Dose)
Siena Biotech S.p.A.
2011 Phase 1 NCT01485952 Germany;
SEN0014196 (Low Dose)
Siena Biotech S.p.A.
2011 Phase 1 NCT01485952 Germany;
SOM3355 100mg BID
SOM Biotech SL
2018 Phase 2 NCT03575676 Spain;
SOM3355 200mg BID
SOM Biotech SL
2018 Phase 2 NCT03575676 Spain;
SRX246
Azevan Pharmaceuticals
2016 Phase 2 NCT02507284 United States;
SS-20
Stealth Bio Therapeutics Inc
2017 Phase 2 EUCTR2016-003730-25-NL Netherlands;
Selisistat
SIENA BIOTECH SPA
2011 - EUCTR2011-001131-23-IT Germany;Italy;United Kingdom;
Siena Biotech SpA
2011 - EUCTR2011-001131-23-GB Germany;Italy;United Kingdom;
2011 - EUCTR2011-001131-23-DE Germany;Italy;United Kingdom;
Sodium phenylbutyrate
University of Rochester
2005 Phase 2 NCT00212316 United States;
TV-5600
Teva Branded Pharmaceutical Products R&D, Inc.
2015 Phase 2 EUCTR2014-000418-75-NL Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
2015 Phase 2 EUCTR2014-000418-75-GB Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
2015 Phase 2 EUCTR2014-000418-75-DE Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
2015 Phase 2 EUCTR2014-000418-75-CZ Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
2014 Phase 2 EUCTR2014-000418-75-PT Canada;Czech Republic;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;United States;
2014 Phase 2 EUCTR2014-000418-75-IT Canada;Czech Republic;France;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2014 Phase 2 EUCTR2014-000418-75-ES Canada;Czech Republic;France;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
TV-7820
TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC
2015 Phase 2 EUCTR2015-000904-24-IT Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
Teva Branded Pharmaceutical Products R&D, Inc
2016 Phase 2 EUCTR2015-000904-24-NL Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2015 Phase 2 EUCTR2015-000904-24-GB Australia;Austria;Canada;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2015 Phase 2 EUCTR2015-000904-24-DE Australia;Austria;Canada;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2015 Phase 2 EUCTR2015-000904-24-AT Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2015 Phase 2 EUCTR2013-001888-23-DK Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2014 Phase 2 EUCTR2013-001888-23-PL Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2014 Phase 2 EUCTR2013-001888-23-NL Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2014 Phase 2 EUCTR2013-001888-23-IT Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2014 Phase 2 EUCTR2013-001888-23-DE Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2014 Phase 2 EUCTR2013-001888-23-AT Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
2014 - EUCTR2013-001888-23-GB Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
Tetrabenazine
Prestwick Pharmaceuticals
2000 Phase 3 NCT00219804 -
William Ondo, MD
2018 Phase 4 NCT02509793 United States;
Tetrabenazine withdrawal
New York Medical College
2013 Phase 4 NCT01834911 United States;
Tiapridal
Assistance Publique - Hôpitaux de Paris
2009 Phase 3 NCT00632645 France;
Tominersen
F. HOFFMANN - LA ROCHE LTD.
2020 Phase 3 EUCTR2018-003898-94-IT Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
F.Hoffmann La-Roche Ltd
2020 Phase 3 EUCTR2018-003898-94-NL Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2020 Phase 3 EUCTR2018-003898-94-AT Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003898-94-GB Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
Triheptanoin
INSERM
2015 Phase 2 EUCTR2014-005112-42-NL France;Netherlands;
2015 Phase 2 EUCTR2014-005112-42-FR France;Netherlands;
Triheptanoin 1g/kg/day
Institut National de la Santé Et de la Recherche Médicale, France
2013 Phase 2 NCT01882062 France;
Triheptanoin oil
Institut National de la Santé Et de la Recherche Médicale, France
2015 Phase 2 NCT02453061 France;Netherlands;
UX007
INSERM
2015 Phase 2 EUCTR2014-005112-42-NL France;Netherlands;
2015 Phase 2 EUCTR2014-005112-42-FR France;Netherlands;
Ubiquinol
University of Rochester
2009 Phase 1 NCT00980694 United States;
Ursodiol
Oregon Health and Science University
2007 Phase 1 NCT00514774 United States;
VX-745
EIP Pharma, Inc.
2019 Phase 2 EUCTR2018-004840-51-GB United Kingdom;
VX15/2503
Vaccinex Inc.
2015 Phase 2 NCT02481674 Canada;United States;
Valbenazine
Neurocrine Biosciences
2020 Phase 3 NCT04400331 Canada;United States;
2019 Phase 3 NCT04102579 Canada;United States;
Vitamin B7
Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (Ciberned)
2021 Phase 2 EUCTR2019-004360-22-ES Spain;
WVE-003
Wave Life Sciences Ltd.
2021 Phase 1/Phase 2 NCT05032196 Australia;Canada;Denmark;France;Germany;Poland;Spain;United Kingdom;
Wave Life Sciences UK Limited
2022 Phase 1;Phase 2 EUCTR2020-004556-15-NL Australia;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Switzerland;United Kingdom;
2021 Phase 1;Phase 2 EUCTR2020-004556-15-PL Australia;Canada;Denmark;France;Germany;Italy;Poland;Spain;United Kingdom;
2021 Phase 1;Phase 2 EUCTR2020-004556-15-IT Australia;Canada;Denmark;France;Germany;Italy;Poland;Spain;United Kingdom;
2021 Phase 1;Phase 2 EUCTR2020-004556-15-FR Australia;Canada;Denmark;France;Germany;Poland;Spain;United Kingdom;
2021 Phase 1;Phase 2 EUCTR2020-004556-15-ES Australia;Canada;Denmark;France;Germany;Italy;Poland;Spain;United Kingdom;
2021 Phase 1;Phase 2 EUCTR2020-004556-15-DK Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
2021 Phase 1;Phase 2 EUCTR2020-004556-15-DE Australia;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Switzerland;United Kingdom;
WVE-120101
Wave Life Science Ltd.
2019 Phase 1;Phase 2 EUCTR2016-005095-10-FR Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;United States;
Wave Life Sciences Ltd.
2020 Phase 1/Phase 2 NCT04617847 Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
2017 Phase 1/Phase 2 NCT03225833 Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
Wave Life Sciences UK Limited
2020 Phase 2 EUCTR2019-003637-42-PL Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
2020 Phase 2 EUCTR2019-003637-42-FR Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
2020 Phase 2 EUCTR2019-003637-42-DK Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
2020 Phase 2 EUCTR2019-003637-42-DE Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
2019 Phase 1;Phase 2 EUCTR2016-005095-10-DK Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
2019 Phase 1;Phase 2 EUCTR2016-005095-10-DE Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
2018 Phase 1;Phase 2 EUCTR2016-005095-10-GB Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;United States;
WVE-120102
WAVE Life Sciences Ltd
2019 Phase 1;Phase 2 EUCTR2016-005142-39-FR Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;United States;
Wave Life Sciences Ltd.
2019 Phase 1/Phase 2 NCT04617860 Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
2017 Phase 1/Phase 2 NCT03225846 Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
Wave Life Sciences UK Limited
2020 Phase 2 EUCTR2019-002178-30-FR Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
2020 Phase 2 EUCTR2019-002178-30-DK Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
2020 Phase 2 EUCTR2019-002178-30-DE Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
2019 Phase 2 EUCTR2019-002178-30-PL Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;
2019 Phase 1;Phase 2 EUCTR2016-005142-39-DK Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2016-005142-39-GB Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;United States;
- Phase 1;Phase 2 EUCTR2016-005142-39-DE Australia;Canada;Denmark;France;Germany;Poland;United Kingdom;United States;
Warfarin
Pfizer
2009 Phase 1 NCT00827034 United States;
Xenazine
Assistance Publique - Hôpitaux de Paris
2009 Phase 3 NCT00632645 France;
Zoloft 50Mg Tablet
Second Affiliated Hospital, School of Medicine, Zhejiang University
2020 Phase 1 NCT04071639 China;
[123I]MNI-420
Institute for Neurodegenerative Disorders
2009 Phase 1 NCT00970229 United States;
[18F]FPEB
Institute for Neurodegenerative Disorders
2009 Phase 1 NCT00870974 United States;
daily citalopram
University of Iowa
2005 Phase 2 NCT00271596 United States;